Pancreatic cancer is one of the leading causes for cancer-related deaths in the United
States. Majority of patients present with unresectable or metastatic disease. For those that …

Background Studies comparing upfront surgery with neoadjuvant treatment in pancreatic
cancer may report only patients who underwent resection and so survival will be skewed …

Ductal adenocarcinoma and its variants account for most pancreatic malignancies. High-
quality multiphase imaging can help to preoperatively distinguish between patients eligible …

Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is
the fourth leading cause of cancer-related deaths in the world. Due to the broad …

Background FOLFIRINOX is a standard treatment for metastatic pancreatic cancer patients.
The effectiveness of neoadjuvant FOLFIRINOX in patients with borderline resectable …

Thanks to the development of modern chemotherapeutic regimens, survival after surgery for
pancreatic ductal adenocarcinoma (PDAC) has improved and pancreatologists worldwide …

Pancreatic cancer is expected to be the second deadliest malignancy in the USA by 2020.
The survival rates for patients with other gastrointestinal malignancies have increased …

Pancreatic ductal adenocarcinoma (PDAC), which accounts for more than 90% of all
pancreatic tumours, is a devastating malignancy with an extremely poor prognosis, as …

Objectives: To establish an evidence-based cut-off to differentiate between early and late
recurrence and to compare clinicopathologic risk factors between the two groups. Summary …

Answer questions and earn CME/CNE Pancreatic cancer is currently one of the deadliest of
the solid malignancies. However, surgery to resect neoplasms of the pancreas is safer and …